AstraZeneca : Une survie globale dans TROPION Lung01 peu concluante
>Marginalement mieux que docetaxel - Hier soir, AZN a présenté de nouvelles données de son célèbre essai TROPION-Lung01 évaluant Dato-DXd par rapport à la chimiothérapie chez des patients adultes atteints d'un cancer du poumon non à petites cellules (NSCLC) localement avancé ou métastatique non squameux et ayant reçu au moins une ligne de traitement antérieure.Dans l'ensemble de la population de l'essai, les résultats de la survie globale sont en faveur de Dato’ ...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.